Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185302
Status:
COMPLETED
Last Update Posted:
2015-12-14
First Post:
2005-09-12
Brief Title:
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Phase II Study of MS-275 a Histone Deacetylase Inhibitor Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG GermanyBayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 309100 | OTHER | Company ID | None |
| 2004-002395-41 | EUDRACT_NUMBER | None | None |